RUNX2 and osteosarcoma: Comparing 22 osteosarcomas, we found that the average mRNA overexpression of RUNX2 was 3.3-fold greater in tumors that had a poor response to neoadjuvant chemotherapy (90% necrosis) than in tumors that had a favorable response (>90% necrosis) [66].